PEEL-388

PEEL-388 is a small molecule drug developed by Peel Therapeutics for the treatment of neuroendocrine tumors. It functions as a DNA topoisomerase I (TOP1) inhibitor, disrupting the enzyme's ability to manage DNA supercoiling during replication and transcription, which leads to DNA breaks and cell death in rapidly dividing tumor cells. The compound is engineered to specifically target neuroendocrine tumors and has demonstrated robust preclinical efficacy in identifying and killing metastatic lesions. As of April 2025, it remains in preclinical development with plans for advancement into IND-enabling studies and phase I clinical trials[1][2][6].